SynapDx snags $6M for autism Dx study

SynapDx, a maker of a blood diagnostics test for autism spectrum disorders, nabbed $6 million in venture funding, enabling executives to proceed with a 600-patient prospective multicenter clinical study for the test. In a trial slated to begin in the 2013 second quarter, researchers will evaluate the measurement of RNA expression differences to accurately diagnose children at risk for autism spectrum disorders. The test is meant to fill a gap in both the diagnosis and treatment of autism, CEO Stanley Lapidus told FierceMedicalDevices. Report | Release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.